Takeda Pharmaceutical Company Limited recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted Adcetris a positive review.
Takeda’s Adcetris now has a CHMP recommendation as a consolidation treatment specifically for post-transplant Hodgkin lymphoma patients. The recommendation only applies to treating adult patients who have CD30+ Hodgkin lymphoma. These patients must show a higher risk for relapse or for progression after they receive their autologous stem cell transplantation (ASCT) treatment.
Approximately 50 percent of patients who have Hodgkin lymphoma experience a relapse after they complete their ASCT. These patients also have additional risk factors, which can cause higher chances of relapsing.
“While ASCT is the standard of care following failure of frontline chemotherapy in Hodgkin lymphoma, we know that many patients will unfortunately see their disease return,” Dirk Huebner, executive medical director of the Oncology Therapeutic Area Unit, Takeda Pharmaceutical Company, said. “Early eradication of residual disease through treatment with Adcetris has the highest chance of preventing the disease from returning in these patients. This opinion, in addition to the recent five-year overall survival data in relapsed or refractory Hodgkin lymphoma, further establishes the role of Adcetris in improving outcomes for patients. We look forward to the European Commission’s authorization of this new indication and bringing this medicine to physicians and patients in the European Union.”
